ES2655076T3 - Unidad de dosificación sólida de desintegración oral con un componente de estetrol - Google Patents
Unidad de dosificación sólida de desintegración oral con un componente de estetrol Download PDFInfo
- Publication number
- ES2655076T3 ES2655076T3 ES14814804.2T ES14814804T ES2655076T3 ES 2655076 T3 ES2655076 T3 ES 2655076T3 ES 14814804 T ES14814804 T ES 14814804T ES 2655076 T3 ES2655076 T3 ES 2655076T3
- Authority
- ES
- Spain
- Prior art keywords
- estetrol
- weight
- estetrol component
- oral disintegration
- dosing unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 title abstract description 18
- 229950009589 estetrol Drugs 0.000 title abstract description 18
- 239000007787 solid Substances 0.000 title abstract description 6
- 239000008187 granular material Substances 0.000 abstract description 11
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 2
- 238000005303 weighing Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 5
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- MCRNHLQVPJEMSQ-UHFFFAOYSA-N C(C=CC(=O)O)(=O)O.C(CCCCCCCCCCCCCCCCC)[Na] Chemical compound C(C=CC(=O)O)(=O)O.C(CCCCCCCCCCCCCCCCC)[Na] MCRNHLQVPJEMSQ-UHFFFAOYSA-N 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 238000007596 consolidation process Methods 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13196904 | 2013-12-12 | ||
| EP13196904 | 2013-12-12 | ||
| PCT/EP2014/077127 WO2015086643A1 (en) | 2013-12-12 | 2014-12-10 | Orally disintegrating solid dosage unit containing an estetrol component |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2655076T3 true ES2655076T3 (es) | 2018-02-16 |
Family
ID=49759137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14814804.2T Active ES2655076T3 (es) | 2013-12-12 | 2014-12-10 | Unidad de dosificación sólida de desintegración oral con un componente de estetrol |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9884064B2 (enExample) |
| EP (1) | EP3079671B1 (enExample) |
| JP (1) | JP6447931B2 (enExample) |
| KR (1) | KR102265150B1 (enExample) |
| CN (1) | CN105979935B (enExample) |
| AU (1) | AU2014363599B2 (enExample) |
| BR (1) | BR112016013502B1 (enExample) |
| CA (1) | CA2932855C (enExample) |
| CL (1) | CL2016001411A1 (enExample) |
| CY (1) | CY1119817T1 (enExample) |
| DK (1) | DK3079671T3 (enExample) |
| EA (1) | EA032306B1 (enExample) |
| ES (1) | ES2655076T3 (enExample) |
| HR (1) | HRP20180129T1 (enExample) |
| HU (1) | HUE035848T2 (enExample) |
| IL (1) | IL246082B (enExample) |
| LT (1) | LT3079671T (enExample) |
| MA (1) | MA39105B1 (enExample) |
| MX (1) | MX369035B (enExample) |
| NO (1) | NO3079671T3 (enExample) |
| NZ (1) | NZ720906A (enExample) |
| PL (1) | PL3079671T3 (enExample) |
| PT (1) | PT3079671T (enExample) |
| RS (1) | RS56738B1 (enExample) |
| SG (1) | SG11201604741UA (enExample) |
| SI (1) | SI3079671T1 (enExample) |
| SM (1) | SMT201700582T1 (enExample) |
| TN (1) | TN2016000230A1 (enExample) |
| WO (1) | WO2015086643A1 (enExample) |
| ZA (1) | ZA201603903B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20161369T1 (hr) | 2011-06-01 | 2016-12-02 | Estetra S.P.R.L. | Postupak za proizvodnju intermedijera estetrola |
| SG195118A1 (en) | 2011-06-01 | 2013-12-30 | Estetra S A | Process for the production of estetrol intermediates |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| PT2741824T (pt) * | 2011-08-11 | 2017-07-06 | Estetra Sprl | Utilização de estetrol como contracetivo de emergência |
| EP3310333B1 (en) | 2015-06-18 | 2020-04-29 | Estetra SPRL | Orodispersible dosage unit containing an estetrol component |
| PL3106148T3 (pl) * | 2015-06-18 | 2018-08-31 | Mithra Pharmaceuticals S A | Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy |
| MD3310346T2 (ro) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
| US10894014B2 (en) | 2015-06-18 | 2021-01-19 | Estetra Sprl | Orodispersible tablet containing Estetrol |
| KR102712911B1 (ko) * | 2016-08-05 | 2024-10-04 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| US20200046729A1 (en) * | 2016-08-05 | 2020-02-13 | Estetra Sprl | Methods using combined oral contraceptive compositions with reduced cardiovascular effects |
| UA126746C2 (uk) * | 2018-02-07 | 2023-01-18 | Естетра Спрл | Композиція контрацептива зі зниженими ефектами щодо серцево-судинної системи |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| JOP20200260A1 (ar) * | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| GB2603868B (en) * | 2019-09-27 | 2023-10-11 | Ind Chimica Srl | Process for preparing (15ALPHA,16ALPHA,17BETA)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-tetrol monohydrate (estetrol monohydrate) and intermediates of said process |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| EP4221693A1 (en) | 2020-09-29 | 2023-08-09 | Millicent Pharma Limited | Orodispersible formulations |
| DE112023005720T5 (de) | 2023-02-02 | 2025-12-11 | Industriale Chimica S.R.L | VERFAHREN ZUR HERSTELLUNG VON (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) MONOHYDRAT |
| CL2025000553A1 (es) | 2024-02-28 | 2025-08-29 | Estetra Srl | Forma polimórfica de estetrol y producción de la misma |
| HUP2400151A1 (hu) | 2024-02-28 | 2025-09-28 | Richter Gedeon Nyrt | Ösztetrol-monohidrát kristályosítási eljárás |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997004752A1 (en) * | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
| US6117446A (en) | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| PT1390040E (pt) | 2001-05-18 | 2007-04-30 | Pantarhei Bioscience Bv | Composição farmacêutica para ser utilizado na terapia hormonal de substituição. |
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| ES2296943T3 (es) | 2001-05-23 | 2008-05-01 | Pantarhei Bioscience B.V. | Sistema de administracion de un medicamento estrogeno tetrahidroxilado destinado a la contracepcion hormonal. |
| WO2002094278A1 (en) * | 2001-05-23 | 2002-11-28 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| WO2003018026A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
| DE60216630T2 (de) | 2001-11-15 | 2007-09-20 | Pantarhei Bioscience B.V. | Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie |
| CA2476940C (en) * | 2002-02-21 | 2011-11-01 | Herman Jan Tijmen Coelingh Bennink | Pharmaceutical compositions comprising one or more steroids, one or more tetrahydrofolate components and vitamin b12 |
| GB0410616D0 (en) | 2004-05-13 | 2004-06-16 | Unilever Plc | Antiperspirant or deodorant compositions |
| US20070048369A1 (en) | 2005-08-26 | 2007-03-01 | National Starch And Chemical Investment Holding Corporation | Mucosal delivery tablet |
| US20090221540A1 (en) | 2006-01-09 | 2009-09-03 | Pantarhei Bioscience B.V. | Method of Treating An Acute Vascular Disorder |
| MX2008014941A (es) * | 2006-06-08 | 2008-12-10 | Warner Chilcott Co Inc | Metodos para administrar formas de dosificacion solida de etinil estradiol y profarmacos del mismo con biodisponibilidad mejorada. |
| US20070286819A1 (en) | 2006-06-08 | 2007-12-13 | Warner Chilcott Company, Inc. | Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability |
| AR064014A1 (es) * | 2006-11-29 | 2009-03-04 | Wyeth Corp | Tabletas bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina |
| AU2007338843B2 (en) * | 2006-12-20 | 2013-05-09 | Teva Women's Health, Inc. | Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
| CN101631536A (zh) * | 2007-01-12 | 2010-01-20 | 惠氏公司 | 片中片组合物 |
| ATE537833T1 (de) * | 2007-06-21 | 2012-01-15 | Pantarhei Bioscience Bv | Behandlung des mekoniumaspirationssyndroms mit östrogenen |
| WO2010033832A2 (en) | 2008-09-19 | 2010-03-25 | Evestra, Inc. | Estriol formulations |
| DE102009007771B4 (de) * | 2009-02-05 | 2012-02-16 | Bayer Schering Pharma Aktiengesellschaft | Bukkales Applikationssystem, 17α-Estradiol enthaltend |
| CN102058604A (zh) * | 2009-11-17 | 2011-05-18 | 北京万全阳光医学技术有限公司 | 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法 |
| WO2014159377A1 (en) | 2013-03-14 | 2014-10-02 | Teva Women's Health, Inc. | Compositions containing tanaproget and natural estrogens |
-
2014
- 2014-12-10 SG SG11201604741UA patent/SG11201604741UA/en unknown
- 2014-12-10 PT PT148148042T patent/PT3079671T/pt unknown
- 2014-12-10 MX MX2016007595A patent/MX369035B/es active IP Right Grant
- 2014-12-10 WO PCT/EP2014/077127 patent/WO2015086643A1/en not_active Ceased
- 2014-12-10 BR BR112016013502-4A patent/BR112016013502B1/pt not_active IP Right Cessation
- 2014-12-10 EP EP14814804.2A patent/EP3079671B1/en active Active
- 2014-12-10 NZ NZ720906A patent/NZ720906A/en unknown
- 2014-12-10 PL PL14814804T patent/PL3079671T3/pl unknown
- 2014-12-10 AU AU2014363599A patent/AU2014363599B2/en not_active Ceased
- 2014-12-10 CA CA2932855A patent/CA2932855C/en active Active
- 2014-12-10 HU HUE14814804A patent/HUE035848T2/en unknown
- 2014-12-10 LT LTEP14814804.2T patent/LT3079671T/lt unknown
- 2014-12-10 HR HRP20180129TT patent/HRP20180129T1/hr unknown
- 2014-12-10 TN TN2016000230A patent/TN2016000230A1/en unknown
- 2014-12-10 US US15/103,180 patent/US9884064B2/en active Active
- 2014-12-10 SI SI201430525T patent/SI3079671T1/en unknown
- 2014-12-10 NO NO14814804A patent/NO3079671T3/no unknown
- 2014-12-10 KR KR1020167018146A patent/KR102265150B1/ko not_active Expired - Fee Related
- 2014-12-10 JP JP2016539161A patent/JP6447931B2/ja not_active Expired - Fee Related
- 2014-12-10 EA EA201691226A patent/EA032306B1/ru unknown
- 2014-12-10 ES ES14814804.2T patent/ES2655076T3/es active Active
- 2014-12-10 SM SM20170582T patent/SMT201700582T1/it unknown
- 2014-12-10 CN CN201480075244.4A patent/CN105979935B/zh not_active Expired - Fee Related
- 2014-12-10 MA MA39105A patent/MA39105B1/fr unknown
- 2014-12-10 DK DK14814804.2T patent/DK3079671T3/en active
- 2014-12-10 RS RS20180016A patent/RS56738B1/sr unknown
-
2016
- 2016-06-07 IL IL246082A patent/IL246082B/en active IP Right Grant
- 2016-06-08 ZA ZA2016/03903A patent/ZA201603903B/en unknown
- 2016-06-08 CL CL2016001411A patent/CL2016001411A1/es unknown
-
2017
- 2017-12-22 US US15/852,187 patent/US9987287B2/en active Active
-
2018
- 2018-01-10 CY CY20181100031T patent/CY1119817T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2655076T3 (es) | Unidad de dosificación sólida de desintegración oral con un componente de estetrol | |
| ES2875966T3 (es) | Preparación de formas farmacéuticas estables | |
| ES2371060T3 (es) | Preparado farmacéutico que comprende un ingrediente activo dispersado sobre una matriz. | |
| CN101460150A (zh) | 用于口腔崩解片剂的可直接压片复合物 | |
| ES2311442T1 (es) | Dosis en forma oral. | |
| ES2822104T3 (es) | Procedimiento para la preparación de un coadyuvante de tableteado, así como coadyuvante de tableteado | |
| ES2317452T3 (es) | Formulaciones de levetiracetam y procedimientos para su preparacion. | |
| JP2009519326A5 (enExample) | ||
| TW201605494A (zh) | 醫藥劑型 | |
| JP6707126B2 (ja) | 経口投与用球状吸着炭を含む錠剤及びその製造方法 | |
| CN1781479B (zh) | 一种马蔺子素分散体系及其制备方法 | |
| CN102846573A (zh) | 水飞蓟宾双层缓释片及其制备方法 | |
| KR101532810B1 (ko) | 당 알콜과 공동 미세화된 엔타카폰의 약학 조성물 | |
| ES2380229T3 (es) | Formas orales sólidas de ebastina | |
| CN101340896A (zh) | 含有低溶解性药物的压缩的固体剂型和其制备方法 | |
| TWI721997B (zh) | 含高含量精胺酸之錠劑 | |
| CN111096953A (zh) | 一种普瑞巴林口崩片的制备方法 | |
| EP2946771B1 (en) | Water-dispersible tablet formulation comprising deferasirox | |
| JP5900702B2 (ja) | 経口投与用医薬組成物 | |
| JP6336078B2 (ja) | 医薬組成物 | |
| WO2016128726A1 (en) | Method of producing a granulated composition | |
| WO2017170763A1 (ja) | 崩壊錠及びその製造方法 | |
| KR101509489B1 (ko) | 발사르탄을 함유하는 고형 경구제형의 제조 방법 | |
| TWI597063B (zh) | 藥物組成物及其製備方法 | |
| RU2289422C2 (ru) | Фармацевтическая композиция на основе ноопепта |